May 9, 2022 -- Dr. Sven Kili, CEO of Antion Biosciences, contends the Swiss company's microRNA (miRNA) technology (miCAR platform) is a new way of approaching allogeneic cell creation by enabling simultaneous silencing of multiple gene targets while overcoming the challenges faced by existing gene editing approaches.
"The miCAR platform allows us to move beyond gene editing into an ability to silence up to six different genes," Kili told ScienceBoard.net at the International Society for Cell & Gene Therapy (ISCT) 2022 annual meeting in San Francisco. "What this does is makes incredibly powerful cells in a very simple, easy way, which has a much lower cost of goods but a much higher ability to have quality cells."
Kili, who is chair of the ISCT 2022 Business Models & Investment Subcommittee and co-chair of the annual meeting, said Antion Biosciences is starting out with a proof-of-concept involving the miCAR platform's use in creating allogeneic T cells with a first indication in T cell malignancies. The company will then progress to solid tumors.
Watch the video below to learn more.
Copyright © 2022 scienceboard.net